TY - JOUR
T1 - The Role of Purported Mucoprotectants in Dealing with Irritable Bowel Syndrome, Functional Diarrhea, and Other Chronic Diarrheal Disorders in Adults
AU - Alonso Cotoner, Carmen
AU - Abril-Gil, Mar
AU - Albert-Bayo, Mercé
AU - Mall, John-P. Ganda
AU - Expósito, Elba
AU - González Castro, Ana Maria
AU - Lobo Álvarez, Beatriz
AU - Santos, Javier
PY - 2021
Y1 - 2021
N2 - Chronic diarrhea is a frequent presenting symptom, both in primary care medicine and in specialized gastroenterology units. It is estimated that more than 5% of the global population suffers from chronic diarrhea. and that about 40% of these subjects are older than 60 years. The clinician is frequently faced with the need to decide which is the best therapeutic approach for these patients. While the origin of chronic diarrhea is diverse, impairment of intestinal barrier function, dysbiosis. and mucosal micro-inflammation are being increasingly recognized as underlying phenomena characterizing a variety of chronic diarrheal diseases. In addition to current pharmacological therapies, there is growing interest in alternative products such as mucoprotectants, which form a mucoadhesive film over the epithelium to reduce and protect against the development of altered intestinal permeability, dysbiosis, and mucosal micro-inflammation. This manuscript focuses on chronic diarrhea in adults, and we will review recent evidence on the ability of these natural compounds to improve symptoms associated with chronic diarrhea and to exert protective effects for the intestinal barrier.
AB - Chronic diarrhea is a frequent presenting symptom, both in primary care medicine and in specialized gastroenterology units. It is estimated that more than 5% of the global population suffers from chronic diarrhea. and that about 40% of these subjects are older than 60 years. The clinician is frequently faced with the need to decide which is the best therapeutic approach for these patients. While the origin of chronic diarrhea is diverse, impairment of intestinal barrier function, dysbiosis. and mucosal micro-inflammation are being increasingly recognized as underlying phenomena characterizing a variety of chronic diarrheal diseases. In addition to current pharmacological therapies, there is growing interest in alternative products such as mucoprotectants, which form a mucoadhesive film over the epithelium to reduce and protect against the development of altered intestinal permeability, dysbiosis, and mucosal micro-inflammation. This manuscript focuses on chronic diarrhea in adults, and we will review recent evidence on the ability of these natural compounds to improve symptoms associated with chronic diarrhea and to exert protective effects for the intestinal barrier.
KW - Adults
KW - Bismuth subsalicylate
KW - Chronic diarrhea
KW - Gelatine tannate
KW - Mucoprotectans
KW - Mucus
KW - Smectite intestinal permeability
KW - Xyloglugan
U2 - 10.1007/s12325-021-01676-z
DO - 10.1007/s12325-021-01676-z
M3 - Article
C2 - 33738725
SN - 1865-8652
SP - 1
EP - 23
JO - Advances in Therapy
JF - Advances in Therapy
ER -